The recalled drops have been linked to the rare bacteria pseudomonas aeruginosa in 68 patients across 16 states, leading to three deaths, four eye removals and eight cases of vision loss.
The FDA visited Global Pharma’s India-based plant in mid-February, 2 1/2 weeks after the recall. An 11-day inspection resulted in 11 observations, including a “manufacturing process that lacked assurance of product sterility,” according to the report.
The lack of sterilization specifically impacted products manufactured between December 2020 and April 2022 that were shipped to the U.S.
Pseudomonas can spread among patients without symptoms, and it can spread among people who have not used the eye drops via touch.
The particular strain of bacteria associated with the outbreak has never been seen before in the U.S., according to the report.
People impacted by the outbreak have reported using different brands of artificial tears, but EzriCare was mostly commonly reported.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.